Cutting Edge Viral and Non-Viral Delivery Platforms for T-Cell Engineering and Beyond

Growing demand for precision therapy and the recent successes with CAR-T cells for cancer treatment has put the spot light on Cell and Gene Therapy Applications. However, the difficulty of delivering relevant payloads into immune and other challenging cells remains to be a major bottle neck to rapid advancement from bench to clinic. Most studies have been focused on using viruses to engineer T cells. At the same time due to safety concerns with viral vectors there is also lot of demand and investment in non-viral based methods to maximize gene editing efficiencies in immune cells especially to meet increasing demand for developing allogeneic immune cell therapies.

 

This talk will cover recent advancements we have made in delivery tools for genome editing, immune cell engineering and in vivo delivery applications. More specifically we will be addressing the following 4 focus areas.

 

 

Learning Objectives: